
    
      This study will compare standard of care treatment for patients with non-muscle invasive
      bladder cancer (NMIBC). Patients will be randomized to one of three arms, Mitomycin C,
      Gemcitabine or no additional treatment immediately following TURBT in the operating suite.
      All treatment, surgical procedures and follow up care will be conducted according to standard
      of care treatment.
    
  